사이클러리온 테라퓨틱스(CYCN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.79 (-3.07%), 시가총액 $0.01B, 52주 범위 $1.08 ~ $6.38.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambrid
사이클러리온 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
사이클러리온 테라퓨틱스의 현재 주가는 $3.79 (-3.07%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
사이클러리온 테라퓨틱스의 시가총액은 약 $0.01B입니다.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system